BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 23573616)

  • 1. [Therapy concept: herceptin with anthracyclines].
    Untch M
    Onkologie; 2002 Dec; 25 Suppl 5():19-21; discussion 21. PubMed ID: 23573616
    [No Abstract]   [Full Text] [Related]  

  • 2. [Therapy concept: herceptin in combination with arimidex].
    von Minckwitz G
    Onkologie; 2002 Dec; 25 Suppl 5():22 ; discussion 22-4. PubMed ID: 23573617
    [No Abstract]   [Full Text] [Related]  

  • 3. Re: Therapy Insight: anthracyclines and trastuzumab--the optimal management of cardiotoxic side effects.
    Magné N; Chargari C
    Nat Clin Pract Oncol; 2008 Nov; 5(11):E1. PubMed ID: 18957967
    [No Abstract]   [Full Text] [Related]  

  • 4. [Combination therapy herceptin+taxotere/Herceptin+navelbine].
    Meden H
    Onkologie; 2002 Dec; 25 Suppl 5():15-6. PubMed ID: 23573614
    [No Abstract]   [Full Text] [Related]  

  • 5. Cardiotoxicity debated for anthracyclines and trastuzumab in breast cancer.
    Brower V
    J Natl Cancer Inst; 2013 Jun; 105(12):835-6. PubMed ID: 23733910
    [No Abstract]   [Full Text] [Related]  

  • 6. [Combination therapy herceptin+xeloda].
    Schaller G
    Onkologie; 2002 Dec; 25 Suppl 5():17-8; discussion 19. PubMed ID: 23573615
    [No Abstract]   [Full Text] [Related]  

  • 7. Never use anthracyclines with trastuzumab: it is time to reconsider the taboo.
    Gianni L
    Breast Cancer Res Treat; 2009 Oct; 117(3):599-601. PubMed ID: 19387827
    [No Abstract]   [Full Text] [Related]  

  • 8. [The development of breast cancer therapy in Germany in 2004].
    Haller U; Winter R; Untch M
    Gynakol Geburtshilfliche Rundsch; 2004 Apr; 44(2):61-2. PubMed ID: 15067227
    [No Abstract]   [Full Text] [Related]  

  • 9. Anthracyclines in the treatment of early-stage breast cancer: ally or adversary?
    Lyman GH
    Cancer Invest; 2010 Mar; 28(3):217-9. PubMed ID: 20128683
    [No Abstract]   [Full Text] [Related]  

  • 10. Breast cancer drug warning.
    Johns Hopkins Med Lett Health After 50; 2012 Dec; 24(11):8. PubMed ID: 23342677
    [No Abstract]   [Full Text] [Related]  

  • 11. Herceptin: help for advanced breast cancer.
    Runowicz CD
    Health News; 2001 May; 7(5):4. PubMed ID: 11851153
    [No Abstract]   [Full Text] [Related]  

  • 12. Chemotherapy-induced cardiotoxicity in women.
    Dempsey KS
    Crit Care Nurs Clin North Am; 2008 Sep; 20(3):343-50. PubMed ID: 18644518
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trastuzumab before breast surgery? Large trial says yes but does not quell debate.
    Rowan K
    J Natl Cancer Inst; 2009 Apr; 101(7):448-9. PubMed ID: 19318626
    [No Abstract]   [Full Text] [Related]  

  • 14. Ongoing debate: anthracyclines and adjuvant treatment of human epidermal growth factor receptor 2-positive breast cancer.
    Mahesh S
    J Clin Oncol; 2012 Dec; 30(35):4445-6; author reply 4446. PubMed ID: 23071231
    [No Abstract]   [Full Text] [Related]  

  • 15. Choosing the best trastuzumab-based adjuvant chemotherapy regimen: should we abandon anthracyclines?
    Burstein HJ; Piccart-Gebhart MJ; Perez EA; Hortobagyi GN; Wolmark N; Albain KS; Norton L; Winer EP; Hudis CA
    J Clin Oncol; 2012 Jun; 30(18):2179-82. PubMed ID: 22614986
    [No Abstract]   [Full Text] [Related]  

  • 16. Cardiac complications and manifestations of chemotherapy for cancer.
    Khawaja MZ; Cafferkey C; Rajani R; Redwood S; Cunningham D
    Heart; 2014 Jul; 100(14):1133-40. PubMed ID: 24326899
    [No Abstract]   [Full Text] [Related]  

  • 17. Prevalence and management of HER2/neu-positive early breast cancer in a single institution following availability of adjuvant trastuzumab.
    Chan A; McGregor SR
    Intern Med J; 2012 Mar; 42(3):267-74. PubMed ID: 21241440
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [DCIS and HER2/neu].
    Tulusan AH
    Onkologie; 2002 Dec; 25 Suppl 5():11-2; discussion 13. PubMed ID: 23573612
    [No Abstract]   [Full Text] [Related]  

  • 19. [Indications and limitations of primary systemic therapy for operable breast cancer].
    Yamamoto N; Suzuki M; Tanabe N
    Nihon Rinsho; 2007 Jun; 65 Suppl 6():500-6. PubMed ID: 17682201
    [No Abstract]   [Full Text] [Related]  

  • 20. [Potential risk and benefit of the combination of trastuzumab to chemotherapy and radiation therapy in non-metastatic breast cancer].
    Belkacémi Y; Laharie-Mineur H; Gligorov J; Azria D
    Cancer Radiother; 2007 Sep; 11(5):266-75. PubMed ID: 17644449
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.